Baylor Study of LDL Lowering Drug Found No Increase of Adverse Events

Mar 14, 2019 | Cholesterol, Positive Results


Baylor College of Medicine researchers took part in the CLEAR (Cholesterol Lowering via bempedoic Acid, an ACL-inhibiting Regimen) Harmony trial have found that while the new drug, bempedoic acid, where taken over approximately a year, did cause some adverse effects, adding bempadoic acid therapy to maximally tolerated strain therapy appeared to have an acceptable safety profile.

Hence the drug has been found to significantly lower LDL cholesterol in those who are being treated with a statin but still have high cholesterol and increased risk of cardiovascular events and does not increase overall adverse events or serious adverse events when compared to a placebo.

The findings were published in the New England Medical Journal.

Lead Research/Investigator

Dr. Christie Ballantyne


Pin It on Pinterest